Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis
Di Bernardo, M. C., Matakidou, A., Eisen, T., Houlston, R. S., GELCAPS Consortium, [Group Author]
(2009)
Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.
LUNG CANCER, 65 (2).
pp. 237-241.
ISSN 0169-5002
Full text not available from this repository.
Abstract
The plasminogen pathway plays an important role in the behavior of many tumors including lung cancer. Hence genetic variants encoding plasminogen activator (PLAU), plasminogen receptor (PLAUR), plasminogen activator inhibitor 1 (PAI-1) and plasminogen activator inhibitor 2 (PAI-2) may contribute to lung cancer prognosis. To investigate this proposition we genotyped PAI-1 A15T, PLAU L141P, PLAUR L317P and PAI-2 S413C variants in 698 patients with lung cancer, 522 with non-small cell (NSCLC) and 176 with small cell lung cancer (SCLC). PAI-1 A15T was significantly associated with overall survival (OS), with carriers of variant alleles having a worse prognosis (hazard ratio (HR) = 1.14; 95% confidence interval [CI]: 1.03-1.26). An association was also detected between OS in NSCLC and carrier status for PAI-2 413C (HR = 1.13; 95% Cl: 1.01-1.24). These common genetic variants identified warrant further evaluation as promising prognostic markers of patient outcome. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
Item Type: | Article |
---|---|
Authors (ICR Faculty only): | Houlston, Richard |
All Authors: | Di Bernardo, M. C., Matakidou, A., Eisen, T., Houlston, R. S., GELCAPS Consortium, [Group Author] |
Uncontrolled Keywords: | Lung cancer; Plasminogen; Polymorphism; Prognosis;BREAST-CANCER; COLORECTAL-CANCER; METASTASIS; MARKER; SYSTEM; STATISTICS; RELEVANCE; SURVIVAL; INVASION; RECEPTOR |
Funding Acknowledgement: | NCRN ; HEAL ; Sanofi-Aventis ; Allan J Lerner Fund ; Cancer Research UK |
Funding Text: | We are grateful to patients for their participation. Funding for this work was undertaken with support primarily from Cancer Research UK. Additional support was provided by NCRN, HEAL and Sanofi-Aventis. Athena Matakidou was the recipient of a clinical research fellowship from the Allan J Lerner Fund. |
Research teams: | ICR divisions > Genetics and Epidemiology > Molecular & Population Genetics ICR divisions > Molecular Pathology > Molecular & Population Genetics |
Depositing User: | Users 10 not found. |
Date Deposited: | 24 Aug 2009 14:16 |
Last Modified: | 10 Feb 2010 11:51 |
URI: | http://publications.icr.ac.uk/id/eprint/8592 |
Actions (login required)
![]() |
View Item |